Catalyst- and excess reagent recycling in aza-Michael additions-Reference-Cited by-同舟云学术

Catalyst- and excess reagent recycling in aza-Michael additions

Published:2024 Issue:12 Volume:22 Page:2465-2473
ISSN:1477-0520
Container-title:Organic & Biomolecular Chemistry
language:en
Short-container-title:Org. Biomol. Chem.

Author:

Maksó Lilla¹,Szele Boglárka¹,Ispán Dávid¹,Gömöry Ágnes²,Mahó Sándor³,Skoda-Földes Rita¹^ORCID

Affiliation:

1. University of Pannonia, Department of Organic Chemistry, Egyetem u. 10, P.O. Box 158, H-8200 Veszprém, Hungary

2. Hungarian Research Network, Research Centre for Natural Sciences, Magyar tudósok körútja 2, H-1117 Budapest, Hungary

3. Chemical Works of Gedeon Richter Plc., 1103 Budapest, Gyömrői út 19-21, Hungary

Abstract

The use of a [bmim][BF4]/nBu-TMG solvent/catalyst mixture was shown to facilitate the recycling of solvents, catalysts and unreacted N-heterocycles (used in excess) in the aza-Michael reaction of various N-heterocycles with a steroidal substrate.

Funder

Nemzeti Kutatási, Fejlesztési és Innovaciós Alap

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/OB/D3OB02073H

Reference58 articles.

1. Auspicious role of the steroidal heterocyclic derivatives as a platform for anti-cancer drugs

2. Recent advances on synthesis and biological activities of C-17 aza-heterocycle derived steroids

3. Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency

4. Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo

5. CYP17 inhibitors for prostate cancer therapy